Shuchi Nahar's Weekend Blog!

Neuland Labs Ltd Q3FY21 Result Update Twitter Handle: @shuchi_nahar   Link to Company Overview of Neuland Labs in detail: https://myweekendspot.blogspot.com/2020/09/neuland-labs-company-snapshot.html The company has announced consecutive another strong quarter of top-line and bottom-line performance. The revenue at Rs.245.6 crores was a 20% improvement over the corresponding quarter of the last fiscal while the margins have shown an upward trajectory and closed at 19.0%. This was driven by growth across the GDS and CMS verticals. The company remains confident of its long-term growth aspirations as well as its margin resilience.  • Total income increased by 20.0% in Q3FY21 on account of secular growth in GDS and CMS. • Prime segment continues growth led by Levetiracetam and Mirtazapine. • Speciality business had a stable quarter led by Deferasirox and Dorzolamide. • CMS business witnessed growth in scale-up projects and higher projects coming up for validation. • Two ...

Neuland Laboratories Limited -  Company Overview  Shuchi.P.Nahar -  @shuchi_nahar Neuland is a leading manufacturer of active pharmaceutical ingredients (APIs) and an end-to-end solution provider for the pharmaceutical industry’s chemistry needs. The Company operates in the market using two main business models - Generic Drug Substances (GDS) where they cater to the needs of the Generic players and Custom Manufacturing Solutions (CMS) where they primarily work with innovators by helping them bring critical products to the market. CDMO is the emerging growth segment of the company with 13 to 17 Molecules in development phase. 1.      Business Performance Neuland lab (NLL) has posted revenue of INR 2,054mn with 13.5% YoY increase, which was 4% below. The revenue growth was mainly driven by the CMS segment, led by 32 molecules (Development + Commercialize) with speciality API segment, which grew by 33.2% in Q1FY21. EBITDA margin expanded by 622bps to...